|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 乳腺癌术后上肢淋巴水肿的危险因素分析显示文摘目的 探讨乳腺癌术后患者发生上肢淋巴水肿的危险因素.方法 回顾性分析2014年1月至2016年6月在武警四川省总队医院接受保留乳房手术或改良根治术的305例乳腺癌患者的临床资料.所有患者均接受腋窝淋巴结清扫.通过臂围测量的方法,诊断患者的上肢淋巴水肿情况.从术后1个月开始由患者自测臂围,每月2次,再通过门诊或电话随访收集患者双上肢臂围数据.所有患者随访时间为1~36个月,中位随访时间为27个月.随访截止日期为2019年6月30日.采用χ2检验或非参数检验(Kruskal-Wallis H检验)比较上肢淋巴水肿患者和非上肢淋巴水肿患者的临床病理特征,采用非条件Logistic回归分析上肢淋巴水肿的危险因素.结果 在随访期内,18例发生同侧上肢淋巴水肿(上肢淋巴水肿组),287例未发生上肢淋巴水肿(非上肢淋巴水肿组),术后上肢淋巴水肿的发生率是5.9%(18/305).上肢淋巴水肿组和非上肢淋巴水肿组患者在腋窝淋巴结清扫、腋窝放射治疗、BMI、糖尿病方面比较,差异均有统计学意义(Z=-3.532,P<0.001;χ2=66.391、4.935、8.196,P均<0.050).Logistic回归分析结果显示,Ⅲ水平腋窝淋巴结清扫、腋窝放射治疗、BMI≥25和糖尿病是乳腺癌患者术后上肢淋巴水肿的危险因素(OR=4.661,95%CI:1.359~15.990,P=0.014;OR=3.548,95%CI:1.311~9.794,P=0.013;OR=4.580,95%CI:1.795~11.628,P=0.001;OR=4.404,95%CI:1.663~11.660,P=0.003).结论 接受Ⅲ水平腋窝淋巴结清扫及腋窝放射治疗、BMI≥25及糖尿病的患者发生术后上肢淋巴水肿的风险较高,应尽早干预,积极预防. | 林武华 陈茜 周琦 | 2020 | 中华乳腺病杂志(电子版)2020，14，3： | 18 |
| 2 | A multi-center investigation of breast-conserving surgery based on data from the Chinese Society of Breast Surgery(CSBrS-005)显示文摘Background:Although breast-conserving surgery is one of the standard treatments for breast cancer,few studies have assessed its recent implementation in China.We aimed to clarify the current real-world status of breast-conserving surgery in China.Methods:This cross-sectional survey relied on data collected by the Chinese Society of Breast Surgery(CSBrS)to examine patients who underwent this surgery between January 2018 and December 2018.The survey was conducted using a uniform electronic questionnaire to collect information,including clinical and pathological data on these patients.Results:Overall,4459 breast-conserving surgeries were performed in 34 member units of CSBrS,accounting for 14.6%of all breast cancer surgeries performed in these units during the study period.In patients who underwent breast-conserving surgery with information on tumor size available,more than half(61.2%)of the tumors were smaller than 2 cm in diameter,and only 87(3.2%)tumors were larger than 4 cm in diameter.Among patients who underwent breast-conserving surgeries,457(10.2%)patients received neoadjuvant therapy before the surgery.Among patients with a reported margin width,34(2.0%)patients had a margin of≤2 mm,and 1530(88.2%)of them had a margin of>5 mm.Conclusions:This study demonstrated the rates of breast-conserving surgery in member units of the CSBrS,and introduced the characteristics and surgical margins of patients who underwent this surgery.This information helps describe the real-world status of breast-conserving surgery in China. | Li-Xiang Yu Peng Shi Xing-Song Tian Zhi-Gang Yu 无 | 2020 | Chinese Medical Journal2020，，22： | 12 |
| 3 | 外周血循环肿瘤细胞和游离DNA联合检测在乳腺癌辅助诊断中的临床价值显示文摘目的探讨外周血液中循环肿瘤细胞(CTCs)和循环游离DNA(cfDNA)检测在乳腺癌患者中的临床价值.方法收集2017年7月至2018年4月就诊于南通大学附属医院的47例乳腺癌患者(Ⅱ期7例、Ⅲ期19例、Ⅳ期21例),24例乳腺良性疾病患者,以及同期28名健康体检者外周血液标本.采用基于尺寸的高通量微流控芯片捕获CTCs、基于Alu序列的实时荧光定量PCR检测游离DNA长、短片段(247bp、115bp),并以长、短片段扩增产物比值作为DNA完整性指标.采用Mann-WhitneyU检验或Kruskal-WallisH检验比较各组差异,分析CTCs和cfDNA与乳腺癌临床参数的关系.绘制ROC曲线并计算曲线下面积(AUC)用于评价血细胞CTCs及血浆cfDNA检测作为诊断标准的可行性.结果47例乳腺癌患者CTCs(13.98±12.36)个/ml、cfDNA的完整性(Alu247/115)(0.7687±0.3868)与正常对照组的(1.14±1.35)个/ml、0.5094±0.2456相比,差异有统计学意义(U值分别为126.5、359.0,P均<0.001);ROC曲线下面积为:CTCs:0.885(95%CI:0.805~0.965),cut-off值为7.68个/ml,灵敏度为80.4%,特异度为96.4%;Alu247/115:0.727(95%CI:0.608~0.847),cut-off值为0.431,灵敏度为71.7%,特异度为71.4%.CTCs和Alu247/115联合检测时曲线下面积为0.919(95%CI0.854~0.984),高于各指标单项检测.结论CTCs与cfDNA可能是乳腺癌辅助诊断的潜在生物学指标,CTCs与cfDNA联合检测可能提高乳腺癌患者的诊断率. | 张潇分 贾春平 陈宏梅 施英娟 鞠少卿 王旭东 储海丹 丛辉 | 2019 | 中华检验医学杂志2019，42，8： | 10 |
| 4 | Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer:Current evidence and future perspectives显示文摘Despite the application of conventional therapies,the prognosis of advanced gastric cancer(GC)or gastroesophageal junction cancer(GEJC)is still poor.In recent years,immune checkpoint inhibitors(ICIs)have reshaped the paradigm of cancer therapy.Emerging evidence support the feasibility of programmed cell death-1(PD-1)and its ligand(PD-L1)inhibition in chemo-refractory GC/GEJC.Nivolumab and pembrolizumab have initially been approved in Japan and United States,respectively for the third-line treatment of progressive GC or GEJC.In March 2020,nivolumab has also been licensed in China for treating advanced GC/GEJC who received≥2 lines of systemic therapies.Current studies are moving forward to the first-line application or focusing on combination strategies,though data are insufficient and disputable.In this review,we summarize the recently reported and ongoing clinical trials in ICIs for advanced GC/GEJC.Molecular characteristics and clinical implications of different tumor subtypes are also reviewed.We further discuss the safety profile and biomarkers for predicting the response of ICIs,which has guiding values in clinical practice. | Zhening Zhang T ong Xie Xiaotian Zhang Changsong Qi Lin Shen Zhi Peng | 2020 | Chinese Journal of Cancer Research2020，32，3： | 10 |
| 5 | A study protocol of population-based cancer screening cohort study on esophageal,stomach and liver cancer in rural China显示文摘Objective:National Health Commission of the People's Republic of China collaborated with many ministries and commissions government and initiated a population-based cancer screening program in high-risk area of rural China,targeting three types of cancer that are most prevalent in these areas,including esophageal,stomach and liver cancer.This study protocol was reported to show the design and evaluate the effectiveness of cancer screening and appropriate screening strategies of three cancers in rural China.Methods and analysis:A two-step design with cancer risk assessment based on questionnaire interview,Hepatitis B surface antigen(HBsAg)test strip and subsequent clinical intervention for high-risk populations was adopted&ee of charge at the local hospitals designated in the program.Ethic and dissemination:This study was approved by the Institutional Review Board of Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College.The results will evaluate the effectiveness of cancer screening and appropriate screening strategies in rural China. | Jiang Li He Li Hongmei Zeng Rongshou Zheng Maomao Cao Dianqin Sun Jiansong Ren Wanqing Chen Jie He | 2020 | Chinese Journal of Cancer Research2020，32，4： | 10 |
| 6 | 胃癌术后感染病原菌及危险因素分析显示文摘目的分析胃癌根治术后感染病原菌特点及其危险因素。方法选择2016年11月-2019年11月信阳市中心医院收治的胃癌手术患者为研究对象,65例术后感染患者为感染组,65例未感染患者为对照组,自拟回顾性流行病学调查表,收集患者年龄、性别、居住地、病史、吸烟状况、病理类型、手术类型、病原菌培养、炎症因子、病程等信息。分析病原菌特点及感染危险因素。结果感染组65例共检出86株病原菌,其中革兰阴性菌占58.14%,革兰阳性菌占37.21%,真菌4.65%。菌种前三位为肺炎克雷伯菌27株、金黄色葡萄球菌21株、铜绿假单胞菌15株,分别占31.40%、24.42%和17.44%。影响胃癌术后感染的单因素分析结果,年龄≥65岁、BMI≥24.0 kg/m^2、农村居住、吸烟史、2型糖尿病、幽门螺杆菌感染、白蛋白<30.0 g/L、住院时间≥20 d等因素两组间比较有统计学意义(P<0.05)。Logistic回归分析,术前血清白蛋白、手术方式、住院天数等胃癌术后感染的OR值>1(P<0.05)。结论胃癌患者术后感染的主要病原菌为肺炎克雷伯菌、金黄色葡萄球菌和铜绿假单胞菌。胃癌患者手术后感染的因素多,术前血清白蛋白、手术方式、住院天数等是胃癌术后感染的独立危险因素。 | 蔡雪娟 余强 芦乙滨 张颖 李丽 宋启红 | 2020 | 中华医院感染学杂志2020，30，6： | 8 |
| 7 | 不断提高中国胃癌外科手术治疗规范化显示文摘胃癌是中国常见的消化道肿瘤之一,手术治疗仍然是根治胃癌的基石。基于国内、日韩和欧美的实践和循证医学证据,已经形成以根治性的胃切除、规范的淋巴结清扫和消化道重建的手术模式。在胃癌外科手术的根治性、安全性基础上,更加注重患者术后长期生活质量。同时近年来,在胃食管结合部腺癌、功能保留胃切除术及微创治疗方面有了一定进展。规范化的胃切除及淋巴结清扫,即高质量的外科手术,是提高胃癌患者预后的重要因素。针对不同分期,外科治疗只有在适当的时机给予精准、规范的治疗,才能使患者获益最大化。 | 韦静涛 季鑫 季加孚 | 2022 | 中华普外科手术学杂志(电子版)2022，16，3： | 7 |
| 8 | 右丙亚胺对表柔比星方案化疗乳腺癌患者表柔比星心脏毒性的预防作用观察显示文摘目的探讨右丙亚胺对乳腺癌患者使用表柔比星化疗引发的心脏毒性的预防作用。方法乳腺癌患者90例,随机分为观察组及对照组各45例,两组均采用表柔比星方案(EC-T,前4个治疗周期静脉滴注50 mg/m^(2)盐酸表柔比星联合500 mg/m^(2)环磷酰胺,后4个治疗周期静脉滴注75 mg/m2序贯多西他赛,共8个治疗周期,每21天为1个治疗周期)化疗。观察组患者使用EC-T方案前30 min快速静脉滴注右丙亚胺,与表柔比星剂量比为10∶1。两组患者第1、3、5、8治疗周期前1 d与化疗后3 d,均采用ELISA法检测天冬氨酸氨基转移酶(AST)、乳酸脱氢酶(LDH)、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、α-羟丁酸脱氢酶(α-HBDH),心脏彩超测量左心室射血分数(LVEF),并行心电图(ECG)检查。结果每个治疗周期前后,对照组各心肌酶均高于治疗前(P均<0.05);每个治疗周期结束后,对照组各心肌酶均高于第1个治疗周期治疗前(P均<0.05),LVEF均低于第1个治疗周期化疗前,但仅第3、5个治疗周期差异有统计学意义(P均<0.05)。每个治疗周期后,除AST指标降低以外,观察组其他心肌酶均高于治疗前,但差异无统计学意义(P均>0.05);每个治疗周期结束后,观察组心肌酶均高于第1个治疗周期治疗前,但差异无统计学意义(P均>0.05);化疗前观察组第3个治疗周期CK、CK-MB及第5个治疗周期CK低于对照组(P均<0.05);化疗后观察组第1个治疗周期AST、LDH、CK,第3个治疗周期AST、LDH、CK、CK-MB,第5个治疗周期AST、α-HBDH、CK、CK-MB以及第8个治疗周期AST均低于对照组(P均<0.05)。每个治疗周期结束后,观察组LVEF均低于第1个治疗周期化疗前,但差异均无统计学意义(P均>0.05);化疗后观察组LVEF高于对照组,但差异无统计学意义(P>0.05);观察组每个治疗周期结束后心脏彩超、心电图异常率均低于对照组(P均<0.05)。结论右丙亚胺对乳腺癌患者使用表柔比星化疗引发的心脏毒性有一定的预防作用。 | 杨孟达 张鹏程 张迅 赵晶晶 张也 晏大学 | 2022 | 山东医药2022，62，15： | 7 |
| 9 | Multi-center investigation of breast reconstruction after mastectomy from Chinese Society of Breast Surgery:A survey based on 31 tertiary hospitals(CSBrS-004)显示文摘Objective:Multi-center data on the current status and trends of breast reconstruction after mastectomy in China are lacking.Herein,we conducted a cross-sectional survey to investigate the current clinical practice pattern of postmastectomy breast reconstruction among Chinese female patients with breast cancer.Methods:A standardized questionnaire used to collect information on breast reconstruction among females diagnosed with breast cancer was distributed by 31 members of the Chinese Society of Breast Surgery between January 1,2018 and December 31,2018.Information was collected on tumor characteristics,treatment,mesh application,nipple-areola complex(NAC)preservation,postoperative complications,bilateral reconstruction,patient satisfaction and local recurrence.The overall rate of breast reconstruction was assessed,and the characteristics were compared across patient groups with different reconstruction approaches.Results:A total of 1,554 patients underwent breast reconstruction after total mastectomy,with a reconstruction rate of 9.6%.Among them,1,190 were implant-based,and 262 underwent autologous reconstructions,while 102 cases underwent a combination of both.Patients who underwent implant-based reconstruction were younger than those who received autologous reconstruction(40.1±4.6 vs.45.0±5.9,P=0.004).Compared to patients with autologous reconstruction,mesh application(25.5%vs.6.5%),NAC preservation(51.8%vs.40.5%)and reconstruction failure(1.8%vs.0)were more frequently reported among those with implant-based reconstruction.There was no significant difference in general satisfaction across three reconstruction approaches,though patients with autologous reconstruction reported the highest aesthetic satisfaction among the three groups(P=0.044).Conclusions:Implant-based breast reconstruction remains the dominant choice among patients,while autologous reconstruction was associated with higher aesthetic satisfaction.Our multi-center investigation based on the findings of the tertiary hospitals of Chinese Society of Breast Surgery may guide a future series of clinical studies on breast reconstruction in China. | Feng Xu Chuqi Lei Heng Cao Jun Liu Jie Li Hongchuan Jiang Chinese Society of Breast Surgery | 2021 | Chinese Journal of Cancer Research2021，33，1： | 7 |
| 10 | Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing显示文摘Objective:To compare the efficacy of platinum-and non-platinum-based regimens as first-line treatment for advanced triple-negative breast cancer(TNBC)and analyze the relationship between their efficacy and BRCA gene status.Methods:Retrospectively analyze clinical data of 220 patients diagnosed pathologically with advanced TNBC and treated at the Department of Breast Oncology,Peking University Cancer Hospital from 2013 to 2018 and evaluate the efficacy of chemotherapy.A total of 114 patients had BRCA1/2 gene tested by next generation sequencing(NGS)using peripheral blood,and we analyzed the correlation between their efficacy and BRCA1/2 gene status.Results:Non-platinum-based chemotherapy(NPCT)was administered to 129 and platinum-based chemotherapy(PBCT)to 91 study patients.The clinical benefit rate(CBR)and median progression-free survival(PFS)were not statistically different between NPCT and PBCT groups.The median overall survival(OS)was 30.0 and 22.5 months for PBCT and NPCT group,respectively[P=0.090,hazard ratios(HR)=0.703].BRCA status was assessed in 114 patients,14 of whom had deleterious germline BRCA1/2(g BRCA)mutations(seven in each group).In PBCT group,the CBR was 85.7%and 35.1%for patients with and without deleterious g BRCA mutations,respectively(P=0.039).The median PFS were 14.9 and 5.3 months and median OS were 26.5 and 15.5 months for patients with and without deleterious g BRCA mutations,respectively(P=0.001,P=0.161,respectively).Patients in PBCT group had significantly greater rates of grade 3-4 anemia(5.5%vs.0%)and thrombocytopenia(8.8%vs.0%),whereas palmar-plantar erythrodysesthesia(12.4%vs.0%)and peripheral neuropathy(8.6%vs.1.1%)occurred more frequently in NPCT group.Conclusions:Platinum-based regimens are more effective in patients with deleterious g BRCA mutations,but no difference in patients without BRCA gene mutations,so non-platinum is an option in patients without BRCA gene mutations considering the toxicity and side effect.And we recommend that patients with advanced TNBC should have BRCA gene test. | Nan Wang Kun Li Wenfa Huang Weiyao Kong Xiaoran Liu Weijie Shi Feng Xie Hanfang Jiang Guohong Song Lijun Di Quanren Wang Jianjun Yu Huiping Li | 2020 | Chinese Journal of Cancer Research2020，32，2： | 7 |
| 11 | Current status of lymph node dissection in gastric cancer显示文摘Gastrectomy with lymph node(LN)dissection has been regarded as the standard surgery for gastric cancer(GC),however,the rational extent of lymphadenectomy remains controversial.Though gastrectomy with extended lymphadenectomy beyond D2 is classified as a non-standard gastrectomy,its clinical significance has been evaluated in many studies.Although hard evidence is lacking,D2 plus superior mesenteric vein(No.14 v)LN dissection is recommended when harbor metastasis to No.6 nodes is suspected in the lower stomach,and dissection of splenic hilar(No.10)LN can be performed for advanced GC invading the greater curvature of the upper stomach,and D2 plus posterior surface of the pancreatic head(No.13)LN dissection may be an option in a potentially curative gastrectomy for cancer invading the duodenum.Prophylactic D2+para-aortic nodal dissection(PAND)was not routinely recommended for advanced GC patients,but therapeutic D2 plus PAND may offer a chance of cure in selected patients,preoperative chemotherapy was considered as the standard treatment for GC with para-aortic node metastasis.There has been no consensus on the extent of lymphadenectomy for the adenocarcinoma of the esophagogastric junction(AEG)so far.The length of esophageal invasion can be used as a reference point for mediastinal LN metastases,and the distance from the esophagogastric junction to the distal end of the tumor is essential for determining the optimal extent of resection.The quality of lymphadenectomy may influence prognosis in GC patients.Both hospital volume and surgeon volume were important factors for the quality of radical gastrectomy.Centralization of GC surgery may be needed to improve prognosis. | Bin Ke Han Liang | 2021 | Chinese Journal of Cancer Research2021，33，2： | 7 |
| 12 | Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2(HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients显示文摘Objective: To assess the long-term effectiveness and safety of trastuzumab in adjuvant therapy for Chinese patients with early-stage human epidermal growth factor 2(HER2)-positive breast cancer in a real-world setting.Methods: This retrospective observational study analyzed the medical records of HER2-positive breast cancer patients between 2000 and 2012 at the Chinese Academy of Medical Sciences. Patients who received adjuvant chemotherapy alone or adjuvant chemotherapy followed by/combined with trastuzumab were included. The Kaplan-Meier method was used to estimate disease-free survival(DFS) and overall survival(OS). Hazard ratios(HR) and 95% confidence intervals(95% CI) were calculated using the Cox regression model.Results: Of the 1,348 patients analyzed, 909 received chemotherapy alone and 439 received chemotherapy plus trastuzumab. The 3-year, 5-year and 10-year DFS rates were 83.70%, 76.38% and 68.94%, respectively, in the chemotherapy-alone cohort, and 90.21%, 86.19% and 83.45% in the chemotherapy plus trastuzumab cohort. The3-year, 5-year and 10-year OS rates were 96.10%, 91.40% and 81.88% in the chemotherapy-alone cohort, and98.17%, 94.91% and 90.01% in the chemotherapy plus trastuzumab cohort. The chemotherapy plus trastuzumab group had a significantly lower risk of disease recurrence and death than the chemotherapy-alone group(DFS:HR=0.50, 95% CI, 0.37-0.68;P<0.001;OS: HR=0.53, 95% CI, 0.34-0.81;P=0.004) after adjusting for covariates.In the 439 patients treated with trastuzumab, multivariate analysis suggested that lymph node positivity, higher T stages, and hormone receptor-negative status were significantly associated with higher risks of disease recurrence,and lymph node positivity and hormone receptor-negative status were significantly associated with higher risks of death. Grade 3/4 adverse events(incidence ≥1%) were more common in patients receiving trastuzumab(54.44% vs.15.73%).Conclusions: Early-stage HER2-positive breast cancer patients treated with trastuzumab plus adjuvant chemotherapy have a significant survival benefit compared with chemotherapy-alone in real-world settings. Lymph node positivity, hormone receptor-negative status, and higher T stages may be associated with higher risks of recurrence, and effective therapy for patients with these factors is required. | Jihong Guo Qing Li Pin Zhang Peng Yuan Jiayu Wang Fei Ma Ying Fan Ruigang Cai Yang Luo Qiao Li Binghe Xu | 2019 | Chinese Journal of Cancer Research2019，31，5： | 6 |
| 13 | Surgical treatment of gastric cancer:Current status and future directions显示文摘Surgery is the most important and effective method for the treatment of gastric cancer.Since the first gastrectomy in the early 19th century,surgical treatment of gastric cancer has undergone more than 100 years of development.With the increasing understanding of gastric cancer and the promotion of a series of clinical trials,the concept of gastric cancer surgery has evolved from the initial'bigger is better'to today’s'standardized surgery'and is developing towards individualized surgery focusing on accurate resection and quality of life.This trend has had a tremendous impact on the development of surgical treatments,such as minimally invasive surgeries,functionpreserving surgeries,and the optimal extent of lymph node dissection.Understanding the development and current status of gastric cancer surgery and exploring the remaining academic controversies are goals that every gastric surgeon should constantly pursue.However,how should gastric cancer surgery develop in the future?What opportunities and challenges will we encounter?In this review,we elaborate on the development and current status of gastric cancer surgery based on a series of clinical studies and discuss the controversy in the development of gastric cancer surgery. | Jiahui Chen Zhaode Bu Jiafu Ji | 2021 | Chinese Journal of Cancer Research2021，33，2： | 6 |
| 14 | 胃癌腹膜转移病人腹腔化疗港并发症发生及危险因素分析显示文摘目的:分析腹腔化疗港并发症发生及相关危险因素。方法:回顾性分析我院323例放置腹腔化疗港病人的临床资料,纳入261例胃癌腹膜转移病人。分析腹腔化疗港在胃癌腹膜转移病人腹腔化疗时发生的并发症及其危险因素。结果:261例中59例(22.6%)发生化疗港相关并发症。其中,皮下积液(25例,42.4%)和化疗港感染(16例,27.1%)是发生较多的并发症。其他是港体倾斜翻转(9例,15.3%),化疗港局部切口裂开(7例,11.9%),导管堵塞(1例,1.7%),和皮下转移(1例,1.7%)。化疗港并发症发生的中位时间为化疗港放置后3.0个月。结合Clavien-Dindo分级方法,将化疗港发生的并发症分为1~4个等级。ECOG评分、血清白蛋白水平、置港流程优化及专业团队放置为化疗港并发症发生的独立危险因素(P<0.05)。ECOG评分为唯一影响并发症分级的关联因素(P<0.05)。结论:腹腔化疗港在胃癌腹膜转移病人腹腔化疗中的应用安全可行,发生并发症可控。ECOG评分、血清白蛋白水平、置港方式是否优化及是否专业团队放置为化疗港并发症发生的独立危险因素。 | 杨中印 李琛 刘文韬 施敏 吴珺玮 郑亚南 朱正伦 华子辰 倪震天 陆晟 燕敏 严超 朱正纲 | 2021 | 外科理论与实践2021，26，1： | 5 |
| 15 | Adipocyte-derived SFRP5 inhibits breast cancer cells migration and invasion through Wnt and epithelial-mesenchymal transition signaling pathways显示文摘Objective:Obesity is closely associated with metastasis in breast cancer patients.Secreted frizzled-related protein 5(SFRP5),one of the novel adipokines with anti-inflammatory properties,is associated with obesity.This study aims to study the role of SFRP5 in the crosstalk between obesity and breast cancer metastasis and identify the underlying mechanism.Methods:3T3-L1 pre-adipocytes were differentiated to mature adipocytes and a hypertrophic adipocyte model was induced with palmitic acid(PA).Cell motility was measured in MDA-MB-231 and MCF-7 breast cancer cells co-cultured with adipocytes conditioned medium(CM)with or without SFRP5 protein.Wnt and epithelialmesenchymal transition(EMT)signal pathways were investigated by western blot.Circulating SFRP5 level in 218 breast cancer patients and the association with clinicopathologic characteristics of breast cancer were further determined.Online databases ENCORI and PREDICT Plus were used to exam the link between SFRP5 and prognosis.Results:Reduced SFRP5 level was detected in the hypertrophic adipocyte model.Recombinant SFRP5 protein inhibited MDA-MB-231 and MCF-7 cells invasion and migration induced by PA-treated adipocyte CM,and SFRP5 inhibition by specific antibody reversed the effect of SFRP5.Furthermore,SFRP5 significantly inhibited Wnt and downstream EMT in breast cancer cells.Low circulating SFRP5 level correlated with body mass index(BMI),lymph node(LN)metastasis,TNM stage and high Ki67 expression in breast cancer patients.Increased SFRP5 level was associated with favorable predicted survival.Kaplan-Meier curves showed high SFRP5 level in tumor tissue was associated with better outcome of breast cancer patients.Conclusions:Our findings demonstrated SFRP5 is a vital adipokine that mediates the crosslink between obesity and the metastatic potential of breast cancer.Promotion of SFRP5 expression in the adipose microenvironment may represent a novel approach for preventing breast cancer metastasis. | Wenzhong Zhou Chunmiao Ye Liang Li Liyuan Liu Fei Wang Lixiang Yu Fei Zhou Yujuan Xiang Yongjiu Wang Gengshen Yin Zhongbing Ma Qinye Fu Qiang Zhang Dezong Gao Shuya Huang Zhigang Yu | 2020 | Chinese Journal of Cancer Research2020，32，3： | 5 |
| 16 | 免气腹腹腔镜胃癌根治术的手术操作规范(2021版)显示文摘腹腔镜技术在胃癌治疗中已得到广泛应用,大量前瞻性研究也证实了其手术安全性。腹腔镜下操作空间多依靠CO_(2)气腹构建,对高龄或心肺基础较差的患者可能增加围手术期并发症的发生风险,因此,自20世纪90年代起以悬吊技术为代表的免气腹技术可在一定程度上替代传统气腹,扩大了腹腔镜胃癌手术的适应证。目前大量免气腹装置的研发推动了此技术在胃癌手术中的普及应用。基于此,我们制定此操作规范,旨在通过介绍新型免气腹悬吊技术的操作要点,规范免气腹腔镜胃癌根治术的手术操作流程,以期为临床进一步推广应用提供参考。 | 崔建新 崔昊 郗洪庆 卢灿荣 陈凛 胡三元 卫勃 | 2022 | 腹腔镜外科杂志2022，27，1： | 5 |
| 17 | Classifying risk level of gastric cancer: Evaluation of questionnaire-based prediction model显示文摘Objective: This study aimed at evaluating the efficacy of the questionnaire-based prediction model in an independent prospective cohort.Methods: A cluster-randomized controlled trial was conducted in Changsha, Harbin, Luoshan, and Sheyang in eastern China in 2015-2017. A total of 182 villages/communities were regarded as clusters, and allocated to screening arm or control arm randomly. Face-to-face interview through a questionnaire interview, including of relevant risk factors of gastric cancer, was administered for each subject. Participants were further classified into high-risk or low-risk groups based on their exposure to risk factors. All participants were followed up until December 31, 2019. Cumulative incidence rates from gastric cancer between high-risk and low-risk groups were calculated and compared using the log-rank test. Cox proportional hazard regression models were applied to estimate hazard ratio(HR) and 95% confidence interval(95% CI).Results: Totally, 89,914 residents were recruited with a mean follow-up of 3.47 years. And 42,015(46.73%)individuals were classified into high-risk group and 47,899(53.27%) subjects were categorized into low-risk group.Gastric cancer was diagnosed in 131 participants, of which 91 were in high-risk group. Compared with the low-risk participants, high-risk individuals were more likely to develop gastric cancer(adjusted HR=2.15, 95% CI,1.23-3.76). The sensitivity of the questionnaire-based model was estimated at 61.82%(95% CI, 47.71-74.28) in a general population.Conclusions: Our questionnaire-based model is effective at identifying high-risk individuals for gastric cancer. | Maomao Cao He Li Dianqin Sun Lin Lei Jiansong Ren Jufang Shi Ni Li Ji Peng Wanqing Chen | 2020 | Chinese Journal of Cancer Research2020，32，5： | 5 |
| 18 | Validity of distress thermometer for screening of anxiety and depression in family caregivers of Chinese breast cancer patients receiving postoperative chemotherapy显示文摘Objective:Family caregivers(FCs)of breast cancer patients play a vital role throughout the treatment process.Psychological distress of FCs is common and often ignored.A simple and effective instrument for screening psychological distress would help in selecting those FCs requiring special attention and intervention.Here,the validity of distress thermometer(DT)in FCs of Chinese breast cancer patients receiving postoperative chemotherapy was assessed,and the prevalence of anxiety and depression was evaluated.Methods:We recruited 200 FCs of hospitalized breast cancer patients in this cross-sectional descriptive study.Before the first cycle of adjuvant chemotherapy,the levels of anxiety and depression among FCs were assessed using DT and Hospital Anxiety and Depression Scale(HADS).In total,191 valid cases were analyzed.HADS was used as the diagnostic standard to assess the effectiveness of DT as a screening tool for anxiety and depression as well as to analyze the diagnostic efficiency of DT at various cutoff points.Results:The definitive prevalence of both anxiety and depression was 8.90%.The mean level of anxiety and depression among FCs was 5.64±3.69 and 5.09±3.85,respectively,both of which were significantly higher than corresponding Chinese norms(P<0.01).The areas under receiver operating characteristic curves of DT for the diagnoses of FCs'anxiety and depression were 0.904 and 0.885,respectively.A cutoff value of 5 produced the best diagnostic effects of DT for anxiety and depression.Conclusions:The levels of both anxiety and depression were higher in the FCs of Chinese breast cancer patients receiving postoperative chemotherapy than the national norm.DT might be an effective tool to initially screen psychological distress among FCs.This process could be integrated into the palliative care of breast cancer patients and warrant further research. | Min Yang Fei Ma Bo Lan Jianqiang Cai Xiaoying Sun Binghe Xu | 2020 | Chinese Journal of Cancer Research2020，32，4： | 5 |
| 19 | Complications and risk factors for complications of implanted subcutaneous ports for intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis显示文摘Objective:Intraperitoneal(IP)chemotherapy through subcutaneous port is an effective treatment for gastric cancer(GC)patients with peritoneal metastasis(PM).The objective of this study is to assess the port complications and risk factors for complications in GC patients with PM.Methods:In retrospective screening of 301 patients with subcutaneous ports implantation,249 GC patients with PM who received IP chemotherapy were screened out for analysis.Port complications and risk factors for complications were analyzed.Results:Of the 249 analyzed patients,57(22.9%)experienced port complications.Subcutaneous liquid accumulation(42.1%)and infection(28.1%)were the main complications,and other complications included port rotation(14.1%),wound dehiscence(12.3%),inflow obstruction(1.7%)and subcutaneous metastasis(1.7%).The median interval between port implantation and occurrence of complications was 3.0 months.Eastern Cooperative Oncology Group(ECOG)performance status[odds ratio(OR),1.74;95%confidence interval(95%CI),1.12-2.69],albumin(OR,3.67;95%CI,1.96-6.86),implantation procedure optimization(OR,0.33;95%CI,0.18-0.61)and implantation groups(OR,0.37;95%CI,0.20-0.69)were independent risk factors for port complications(P<0.05).ECOG performance status was the only factor that related to the grades of port complications(P=0.016).Conclusions:Port complications in GC patients who received IP chemotherapy are manageable.ECOG performance status,albumin,implantation procedure and implantation group are independent risk factors for port complications in GC patients with PM. | Zhongyin Yang Chen Li Wentao Liu Yanan Zheng Zhenglun Zhu Ziehen Hua Zhentian Ni Sheng Lu Min Yan Chao Yan Zhenggang Zhu | 2020 | Chinese Journal of Cancer Research2020，32，4： | 5 |
| 20 | PhaseⅠdose-escalation and expansion study of PARP inhibitor,fluzoparib(SHR3162),in patients with advanced solid tumors显示文摘Objective:Fluzoparib(SHR3162)is a novel,potent poly(ADP-ribose)polymerases(PARP)1,2 inhibitor that showed anti-tumor activity in xenograft models.We conducted a phaseⅠ,first-in-human,dose-escalation and expansion(D-Esc and D-Ex)trial in patients with advanced solid cancer.Methods:This was a 3+3 phaseⅠD-Esc trial with a 3-level D-Ex at 5 hospitals in China.Eligible patients for DEsc had advanced solid tumors refractory to standard therapies,and D-Ex enrolled patients with ovarian cancer(OC).Fluzoparib was administered orally once or twice daily(bid)at 11 dose levels from 10 to 400 mg/d.Endpoints included dose-finding,safety,pharmacokinetics,and antitumor activity.Results:Seventy-nine patients were enrolled from March,2015 to January,2018[OC(47,59.5%);breast cancer(BC)(16,20.3%);colorectal cancer(8,10.1%),other tumors(8,10.1%)];48 patients were treated in the D-Esc arm and 31 in the D-Ex arm.The maximum tolerated dose(MTD)was 150 mg bid,with a half-life of 9.14 h.Grade 3/4 adverse events included anemia(7.6%)and neutropenia(5.1%).The objective response rate(ORR)was 30%(3/10)in patients with platinum-sensitive OC and 7.7%(1/13)in patients with BC.Among patients treated with fluzoparib≥120 mg/d,median progression-free survival(m PFS)was 7.2[95%confidence interval(95%CI),1.8-9.3]months in OC,9.3(95%CI,7.2-9.3)months in platinum-sensitive OC,and 3.5(range,2.0-28.0)months in BC.In patients with germline BC susceptibility gene mutation(g BRCAMut)(11/43 OC;2/16 BC),m PFS was 8.9 months for OC(range,1.0-23.2;95%CI,1.0-16.8)and 14 and 28 months for BC(those two patients both also had somatic BRCAMut).Conclusions:The MTD of fluzoparib was 150 mg bid in advanced solid malignancies.Fluzoparib demonstrated single-agent antitumor activity in BC and OC,particularly in BRCAMut and platinum-sensitive OC. | Huiping Li Rongrui Liu Bin Shao Ran Ran Guohong Song Ke Wang Yehui Shi Jihong Liu Wenjing Hu Fu Chen Xiaoran Liu Gairong Zhang Chuanhua Zhao Ru Jia Quanren Wang Hope S.Rugo Yifan Zhang Guangze Li Jianming Xu | 2020 | Chinese Journal of Cancer Research2020，32，3： | 4 |
您所在的机构暂未开通此部分的功能，请联系管理员